Compare DRCT & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRCT | PPCB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | Australia |
| Employees | N/A | 2 |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | 2021 | N/A |
| Metric | DRCT | PPCB |
|---|---|---|
| Price | $0.61 | $0.11 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 105.0K | ★ 6.3M |
| Earning Date | 05-08-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,694,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.10 |
| 52 Week High | $6.04 | $10.69 |
| Indicator | DRCT | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 42.85 |
| Support Level | $0.52 | N/A |
| Resistance Level | $0.79 | $0.13 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 21.04 | 17.23 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.